Cytochrome P450 2D6 genotyping-13652

Test info

  
Cytochrome P450 2D6 genotyping
  
13652
  
LAB13652
  
CYTOP4502D6
  
DME Genotyping
GeneSight
PGx
Pharmacogenomics
Pharmacogenetics
  

Cytochrome P450 2D6 (CYP2D6) is a drug-metabolizing enzyme involved in the metabolism of more than 65 clinically important drugs including some antidepressants, anti-psychotics, opioids, beta-blockers, antiemetics, atomoxetine and tamoxifen. Individuals with some variant CYP2D6 alleles may experience a reduced therapeutic response and may be at risk for side effects from drugs that are metabolized by CYP2D6. CYP2D6 genotype information can be utilized to predict CYP2D6 metabolic phenotype, which can be used as an aid in determining a therapeutic strategy for drugs that are metabolized by CYP2D6. For example, CYP2D6 ultrarapid metabolizers may experience exaggerated side effects after the administration of codeine, while poor metabolizers may experience a reduced analgesic effect due to insufficient biotransformation into morphine. In these instances, alternative drugs may be considered.

Variation in the CYP2D6 gene can result in ultrarapid (UM), normal (NM), intermediate (IM) and poor (PM) drug-metabolizing phenotypes. Depending upon the genotype, a range between some of these phenotypes may be predicted by this assay. In general, relative to the *1 allele (normal function), *2, *35 and *53 alleles have normal function. *9, *10, *14, *17, *29, *41, *49 and *59 alleles have decreased function, while *3, *4, *5, *6, *7, *8, *11, *12, *13, *15, *31, *36, *40, *42 and *68 alleles have no function.

  

The exact effect of a particular genotype on individual drugs can vary. In addition to genotype, the metabolism of drugs may be influenced by additional factors that include environmental, dietary and other medications; these factors and others should be considered prior to initialing a new therapy. All results must be interpreted in the context of other test results and clinical findings. Results do not rule out the possibility of other variant alleles in CYP2D6 or other variant alleles in other drug metabolism pathways. Patients should speak with their healthcare provider about the individual results of this test.

Molecular-based testing is highly accurate, but as in any laboratory test, rare diagnostic errors may occur.

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

Specimen

  
EDTA whole blood
  
  
2.0 mL
  
1.0 mL
  

Immediately following collection, mix sample thoroughly by gentle inverting 8 - 10 times, to prevent clotting

  

Lavender (EDTA), 4 mL

  
ACD whole blood
  

Yellow ACD (A or B)

 

  

Yellow ACD (A or B)

  

Molecular Medicare billing request

Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.

  

Ambient (preferred) - 28 days

Refrigerated - 28 days

Frozen - 2 years

  
  • Hemolysis
  • Quantity not sufficient for analysis (QNS) 
  • Improper container

 

Performance

  
LabCorp (512150): R-LC
  
Twice per week
  
7 - 10 days
  

DNA analysis is performed by allele-specific real-time polymerase chain reactions (RT-PCR) to detect single-nucleotide polymorphisms (SNPs), insertions or deletions (indels), hybrid, hybrid tandem and copy number variants (CNVs) within CYP2D6 gene and to assign variant CYP2D6 *2, *3, *4, *5 (deletion), *6, *7, *8, *9, *11, *12, *13 (hybrid), *13, *15, *17, *29, *31, *35, *36 (hybrid), *36+*10 (hybrid tandem), *40, *41, *42, *49, *53, *59 and *68 (hybrid) alleles and gene duplications (DUPS; copy number (CN) designated). *1 denotes detection of the reference (wild-type) sequence at the assessed alleles. No other variants in this gene are detected by this assay.

Analysis for the *42 allele is dependent upon adequate DNA concentration

Clinical and Interpretive info

  

An interpretive report will be provided

Billing

  
This test may require preauthorization from the insurance provider. Check the payer guidelines and, if needed, obtain the pre-authorization prior to sample collection.
  
81226
  
Yes
  

Medical necessity

Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.

Molecular Medicare billing request

  
Result 40425-1
  

Medical necessity

Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.

Molecular Medicare billing request

Tracking

  
04/23/2019
  
09/03/2024
  
06/05/2023